意义：尽管光动力疗法在临床实践中广泛使用，但缺乏根据光照射期间变化的组织参数来评估肿瘤光动力暴露是否充分的个性化方法。这可能会导致不同的治疗结果。目的：本文的目的是对肿瘤个性化光动力治疗的隐式剂量监测所使用的设备和方法进行全面审查。方法：该综述包括 2010 年 1 月至 2024 年 4 月期间发表的 88 篇同行评审研究文章，这些文章采用了隐式监测方法，例如荧光成像和漫反射光谱。此外，它还包含在临床前和临床实践中最常且成功地用于预测治疗结果的计算机建模方法。使用互联网搜索引擎Google Scholar和Scopus数据库来检索文献中的相关文章。结果：该综述分析并比较了 88 篇同行评审研究文章的结果，这些文章介绍了光动力治疗期间隐式剂量测定的各种方法。 PDT 最重要的波长位于可见光和近红外光谱范围内，例如 405、630、660 和 690 nm。结论：开发一种准确、可靠且易于实施的光动力治疗剂量测定方法仍然是当前的问题，因为确定特定肿瘤的有效光剂量是实现积极治疗结果的决定性因素。

Significance: Despite the widespread use of photodynamic therapy in clinical practice, there is a lack of personalized methods for assessing the sufficiency of photodynamic exposure on tumors, depending on tissue parameters that change during light irradiation. This can lead to different treatment results. Aim: The objective of this article was to conduct a comprehensive review of devices and methods employed for the implicit dosimetric monitoring of personalized photodynamic therapy for tumors. Methods: The review included 88 peer-reviewed research articles published between January 2010 and April 2024 that employed implicit monitoring methods, such as fluorescence imaging and diffuse reflectance spectroscopy. Additionally, it encompassed computer modeling methods that are most often and successfully used in preclinical and clinical practice to predict treatment outcomes. The Internet search engine Google Scholar and the Scopus database were used to search the literature for relevant articles. Results: The review analyzed and compared the results of 88 peer-reviewed research articles presenting various methods of implicit dosimetry during photodynamic therapy. The most prominent wavelengths for PDT are in the visible and near-infrared spectral range such as 405, 630, 660, and 690 nm. Conclusions: The problem of developing an accurate, reliable, and easily implemented dosimetry method for photodynamic therapy remains a current problem, since determining the effective light dose for a specific tumor is a decisive factor in achieving a positive treatment outcome.